Sublingual Semaglutide vs. The Weekly Shot: What's Known And What Isn't
If needles are the thing keeping you from trying a GLP-1, an under-the-tongue version sounds like the answer. It can be a reasonable option. Before you choose it, it helps to know how it differs from the weekly shot, and how much less is known about it.
Same Molecule, Different Route
Both contain semaglutide, the active ingredient in Ozempic® and Wegovy®. The injection goes under the skin once a week. The sublingual version is held under the tongue so it can be absorbed through the lining of the mouth instead of being swallowed. The sublingual semaglutide and the semaglutide-with-additives injection offered through Osirius are prepared by a licensed compounding pharmacy. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety or effectiveness.
Why Semaglutide By Mouth Is Hard
Semaglutide is a peptide, and the digestive tract breaks peptides down easily. Rybelsus®, the FDA-approved semaglutide tablet for type 2 diabetes, gets around this with an absorption enhancer called salcaprozate sodium, much larger doses than the shots use, and strict rules: take it on an empty stomach with no more than 4 ounces of plain water, then wait at least 30 minutes before eating, drinking, or taking other medicines. Even then, its labeling estimates that only about 0.4% to 1% of each dose reaches the bloodstream. Rybelsus is swallowed, so it is a different product from a sublingual one, but it shows how much the route matters.
What The Evidence Covers
The weight-loss results people quote for semaglutide come from large trials of FDA-approved products, such as the STEP trials of the weekly Wegovy® injection. Compounded sublingual semaglutide hasn’t gone through that kind of testing or FDA review, so those results can’t simply be carried over to it. How much medicine you absorb from an under-the-tongue dose, and how consistently, hasn’t been established the way it has for the approved products. Our guide to compounded vs. brand-name GLP-1s goes deeper on that difference.
The Safety Rules Are The Same
The route doesn’t change what semaglutide is. FDA labeling for semaglutide carries a boxed warning about thyroid C-cell tumors seen in rodents, and it should not be used by anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Labeling also warns about pancreatitis, gallbladder problems, kidney injury from dehydration, and low blood sugar when combined with insulin or sulfonylureas. Nausea, diarrhea, vomiting, and constipation are the most common side effects.
Get care right away for severe stomach pain that won’t go away, with or without vomiting, or for a lump or swelling in your neck, trouble swallowing, or shortness of breath.
Who Each One Tends To Fit
The weekly shot has the deeper evidence base, and the brand-name versions are FDA-approved; our guide to Ozempic vs. Wegovy and Mounjaro vs. Zepbound explains how those differ. Sublingual can make sense if needles are a genuine barrier and you are comfortable choosing a less-studied option. Your other medications, health history, and budget matter as much as the route.
Where To Start
A licensed provider reviews your history, current medications, and goals, and decides which option, if any, is appropriate, and at what dose.
This guide explains general information and is not medical advice. It doesn't replace a licensed provider reviewing your own history.